Aptevo Therapeutics Inc. (APVO) is a Seattle-based clinical-stage biotechnology company developing bispecific and trispecific immuno-oncology therapies. Its lead candidate, mipletamig, is being tested in the RAINIER Phase 1b/2 trial in frontline acute myeloid leukemia in combination with venetoclax and azacitidine. The company has no product revenue and a market capitalization of roughly $1.1 million.
Shares last changed hands at $0.4069, down 8.77% from the prior session's close of $0.446 — a decline of about 3.9 cents. The direction is unambiguously negative. No company-specific news release was published during the session, so the move reflects the ongoing repricing of a heavily diluted equity rather than a discrete new event.
The decisive development for the stock remains the November 11 warrant inducement agreement, which closed on November 12. Existing warrant holders agreed to exercise 2,777,778 warrants in cash at a repriced $1.08 per share, delivering approximately $3.0 million in gross proceeds. In return, Aptevo issued new unregistered warrants covering 13,888,890 shares — 500% of the exercised amount — at the same $1.08 strike, exercisable only after stockholder approval and expiring five years later.
For a company of this size, that structure is heavily dilutive relative to the cash raised. The potential $15.0 million of additional proceeds if every new warrant is exercised matters far less today than the near-fivefold increase in potential share count it represents. Crucially, the deal was struck at $1.08 while the stock now trades near $0.41, meaning every new warrant sits far out of the money and the overhang is likely to cap rallies rather than support them. The company has run a similar playbook before, including a comparable financing in August 2026 struck at $4.03, which itself followed a $60 million standby equity facility signed earlier in the year.
The November 16 third-quarter report added context rather than relief. Aptevo disclosed a net loss of $6.55 million for the quarter ended September 30, 2026, against no revenue, with a nine-month loss of $19.6 million. Against that burn rate, $3.0 million in gross proceeds represents weeks of runway, not a funded path to commercialization. Each successive capital raise has been priced lower than the last, and each has added share count, which explains why the equity has repriced so violently even as the underlying clinical narrative — an 81% remission rate in evaluable frontline AML patients — has not deteriorated.
With a float of only about 2.3 million shares, Aptevo's order book is thin enough that modest selling pressure produces outsized percentage moves. The stock has closed lower in seven of the last eight sessions and sits far below both its 50-day moving average near $1.51 and its 200-day moving average near $3.88. A relative strength index reading close to 10 places it in deeply oversold territory, yet buyers have repeatedly failed to hold intraday rebounds — the pattern seen again today, when an early pre-market advance above $0.45 gave way to a new 52-week low.
Volume in recent sessions has run well above the 20-day average of roughly 132,000 shares, with more than 395,000 shares changing hands on November 18 and roughly 281,000 on November 11, the day the financing was announced. That volume profile is consistent with distribution into strength rather than accumulation. The move was idiosyncratic: broad small-cap biotech indices and clinical-stage peers were not down by a comparable margin, and the decline cannot be attributed to sector or macro pressure. There were no meaningful support levels left beneath the price after the break below $0.50 earlier this week.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Aptevo lands at 20 out of 100.
The verified news backdrop is a small but genuinely dilutive financing for a company with a sub-$2 million valuation, already several sessions old and therefore largely reflected in the price. Today's decline of 8.77% was roughly twice the stock's average absolute daily move of about 4.5% over the past 60 sessions, and moves of that size or larger occurred seven times in that window. With no fresh catalyst and a repetition rate this high, both components score low and combine into a modest total.
The nearest scheduled item is the special meeting of stockholders required to approve the inducement warrants; a preliminary proxy was filed on November 13. Approval would make the new warrants exercisable and formalize the overhang. Beyond that, investors will focus on the December 12–15 ASH annual meeting, where mipletamig data in frontline AML is expected to be presented, and on completion of the RAINIER trial by year-end, ahead of a planned Phase 2 start in 2027. Sustained trading below $1 also leaves the shares exposed to Nasdaq's minimum bid price requirement, a compliance risk that typically forces a reverse split. With one analyst covering the name and no revenue, headline risk in both directions remains elevated.
Tickeron's Trending AI Robots page curates the strongest-performing algorithmic traders under current market conditions. The platform hosts hundreds of AI trading bots spanning thousands of tickers, and each bot differs by strategy, timeframe, performance metrics and the specific symbols it trades. Rather than listing the full catalog, this section highlights only the bots posting the best results right now, making it a practical starting point for investors who want to see how automated strategies are positioned. Review the current leaders and compare their track records before deciding what fits your approach.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for APVO turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 43 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.592). P/E Ratio (0.003) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of immunology and cancer research services
Industry Biotechnology